Discovery Programs (Novel 5-HT2A agonists)
Opioid Use Disorder and Treatment-Resistant Depression
PreclinicalIn development
Key Facts
Indication
Opioid Use Disorder and Treatment-Resistant Depression
Phase
Preclinical
Status
In development
Company
About atai Life Sciences
AtaiBeckley, formed from the strategic combination of atai Life Sciences and Beckley Psytech, is a global biotech leader focused on transforming mental healthcare through novel psychedelic-derived therapeutics. Its core strategy employs a decentralized platform to identify, incubate, and fund subsidiary programs, de-risking development across a diversified pipeline. Key near-term catalysts include Phase 2 readouts for its lead programs—BPL-003 and VLS-01 in treatment-resistant depression and EMP-01 in social anxiety disorder—positioning it at the forefront of a potentially paradigm-shifting treatment modality.
View full company profile